Healthcare providers use aromatase inhibitors to treat hormone receptor-positive (ER-positive) breast cancer
And they may be an option for people who no longer benefit from tamoxifen treatment or whose treatment is completed
Three aromatase inhibitors (AIs) are now FDA approved and have been shown to be more effective than the antiestrogen tamoxifen and are well tolerated
Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors
We investigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of nuclear
NFκB pathway is required for the survival and regrowth of tamoxifen-tolerant cells in vitro and in vivo
While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs are associated with musculoskeletal adverse effects known as the aromatase inhibitor
Introduction